Statement of Changes in Beneficial Ownership (4)
May 14 2021 - 7:16PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
OLDAKOWSKI MARK |
2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc
[
BNGO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Operating Officer |
(Last)
(First)
(Middle)
C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/12/2021 |
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 5/12/2021 | | A | | 240000 (1) | A | $0.00 | 252086 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. |
(2) | Includes: 495 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on December 10, 2018, 1,021 shares acquired under the ESPP on June 10, 2019, 1,405 shares acquired under the ESPP on December 10, 2019, 1,199 shares acquired under the ESPP on June 10, 2020 and 1,151 shares acquired under the ESPP on December 10, 2020. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
OLDAKOWSKI MARK C/O BIONANO GENOMICS, INC. 9540 TOWNE CENTRE DRIVE, SUITE 100 SAN DIEGO, CA 92121 |
|
| Chief Operating Officer |
|
Signatures
|
/s/ R. Erik Holmlin, Attorney-in-Fact | | 5/14/2021 |
**Signature of Reporting Person | Date |
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024